Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Llama antibodies show "significant potential" as COVID-19 treatment
Nanobodies are small, simple types of antibodies generated by llamas and camels.
Nanobodies "are among the most effective SARS-CoV-2 neutralising agents we have ever tested" - PHE.  

Scientists at the Rosalind Franklin Institute have discovered a unique type of antibody produced by llamas that could have “significant potential” as a treatment for COVID-19.

Their study, published in the journal Nature Communications, shows that nanobodies – small, simple types of antibodies generated by llamas and camels – can effectively target the SARS-CoV-2 virus responsible for COVID-19.

The team identified short chains of the molecules – which can be produced in the laboratory in large quantities – that can significantly reduce signs of COVID-19 when given to infected animals.

Following clinical studies in humans, scientists say the antibodies could be administered via a simple nasal spray.

Public Health England said the findings have “significant potential for both the prevention and treatment of COVID-19”, adding that the nanobodies “are among the most effective SARS-CoV-2 neutralising agents we have ever tested.” 

It is hoped the discovery could provide a cheaper and more simple alternative to human antibodies taken from patients who have recovered from he disease.

“Nanobodies have a number of advantages over human antibodies," commented lead author Professor Ray Owens, head of protein production at the Rosalind Franklin Institute. "They are cheaper to produce and can be delivered directly to the airways through a nebuliser or nasal spray, so can be self-administered at home rather than needing an injection. 

“This could have benefits in terms of ease of use by patients but it also gets the treatment directly to the site of infection in the respiratory tract,” he said.

In the study, researchers grew the nanobodies by injecting a portion of the SARS-CoV-2 spike protein into a llama called Fifi, who is part of the antibody production facility at the University of Reading. 

Fifi did not become sick as a result of the injection, but it did trigger her immune system to fight off the virus protein by generating nanobodies against it. The team were able to purify four nanobodies capable of binding to the COVID-19 virus from a small blood sample. 

They then combined the nanobodies together into chains of three to increase their ability to bind to the virus, which is then produced in cells in the laboratory.

One of the chains was administered to hamsters infected with SARS-CoV-2, which showed “a marked reduction in disease” with the animals losing far less weight after seven days than untreated hamsters, and having a lower viral load.

“Because we can see every atom of the nanobody bound to the spike, we understand what makes these agents so special," said Professor James Naismith, director of the Rosalind Franklin Institute, who helped lead the research.

“While vaccines have proven extraordinarily successful, not everyone responds to vaccination and immunity can wane in individuals at different times. Having medications that can treat the virus is still going to be very important, particularly as not all of the world is being vaccinated at the same speed and there remains a risk of new variants capable of bypassing vaccine immunity emerging.”

Become a member or log in to add this story to your CPD history

Vets to run marathon for World Animal Protection

News Story 1
 Two recently graduated veterinary surgeons will be running the London Marathon in April to raise money for the charity World Animal Protection.

Alex Bartlett and Maeve O'Neill plan to run the race together if they are given the same start times.

Dr O'Neill said: "You're always limited in what you can do to help animals, so it is nice to raise money for a charity that helps animals around the world."

Dr Bartlett added: "I have never run a marathon before and am excited to run my first one for such a good cause!"

Both Dr Bartlett and Dr O'Neill have fundraising pages online. 

Click here for more...
News Shorts
BSAVA releases new Guide to Procedures

The British Small Animal Veterinary Association (BSAVA) has published a new edition of its Guide to Procedures for Small Animal Practice.

It has added four new procedures; cystostomy tube placement, endotracheal intubation, point-of-care ultrasound and wet-to-dry dressings.

BSAVA says that it is an essential step-by-step guide to diagnostic and therapeutic procedures performed in practice. The textbook includes new images and illustrations, as well as high-definition videos for use prior to procedures.

Nick Bexfield and Julia Riggs, editors of the new edition, said: "We have built upon the success of the previous editions by responding to the feedback received from the BSAVA readership, and hope this new guide helps to further increase the confidence and accuracy with which these procedures are performed."

Print copies are available in the BSAVA store, with a digital version in the BSAVA library.